Publications by authors named "Jeffrey S Weber"

100Publications

Management of Melanoma during Pregnancy: A Case Series of 11 Women Treated at NYU Langone Health.

Oncology 2020 Sep 7:1-6. Epub 2020 Sep 7.

Interdisicplinary Melanoma Cooperative Group, New York, New York, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506811DOI Listing
September 2020

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.

Eur J Cancer 2020 Sep 7;137:171-174. Epub 2020 Aug 7.

Health Economics and Outcomes Research, Bristol Myers Squibb, 100 Nassau Park Blvd, Princeton, NJ, 08540, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.07.011DOI Listing
September 2020

TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?

Clin Cancer Res 2020 May 26;26(9):2085-2086. Epub 2020 Feb 26.

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0387DOI Listing
May 2020

Osteochondral Defect of the Calcaneocuboid Joint: A Case Study.

J Foot Ankle Surg 2019 May 23;58(3):567-572. Epub 2019 Feb 23.

Fellowship-Trained Foot and Ankle Surgeon, Orthopedic Foot and Ankle Center, Westerville, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jfas.2018.09.013DOI Listing
May 2019

Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.

Cancer Immunol Res 2018 10;6(10):1122-1128

Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0214DOI Listing
October 2018

Challenging Cases: Management of Immune-Related Toxicity.

Authors:
Jeffrey S Weber

Am Soc Clin Oncol Educ Book 2018 May;38:179-183

From the Laura and Isaac Perlmutter Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_209557DOI Listing
May 2018

Immunotherapy in the adjuvant setting for high-risk melanoma.

Authors:
Jeffrey S Weber

Clin Adv Hematol Oncol 2018 Aug;16(8):546-548

NYU School of Medicine, New York, New York.

View Article

Download full-text PDF

Source
August 2018

Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.

Cancer 2018 05 15;124(10):2254-2255. Epub 2018 Mar 15.

Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31261DOI Listing
May 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

New Fixation Methods for the Treatment of the Diabetic Foot: Beaming, External Fixation, and Beyond.

Clin Podiatr Med Surg 2018 Jan 3;35(1):63-76. Epub 2017 Oct 3.

Orthopedic Foot and Ankle Center, 300 Polaris Parkway, Westerville, OH 43082, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpm.2017.08.001DOI Listing
January 2018

Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

Cancer 2018 01 12;124(2):297-305. Epub 2017 Oct 12.

Georgetown Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30946DOI Listing
January 2018

Reply to F. Liang et al.

J Clin Oncol 2017 06 6;35(17):1968. Epub 2017 Mar 6.

Jeffrey S. Weber, NYU Langone Medical Center, New York, NY; and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.2645DOI Listing
June 2017

Biomarkers for Checkpoint Inhibition.

Authors:
Jeffrey S Weber

Am Soc Clin Oncol Educ Book 2017 ;37:205-209

From the Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175463DOI Listing
December 2017

PD-1 and PD-L1 antibodies in cancer: current status and future directions.

Cancer Immunol Immunother 2017 May 17;66(5):551-564. Epub 2017 Feb 17.

Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, 522 First Avenue, 1310 Smilow Research Building, New York, NY, 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-1954-6DOI Listing
May 2017

Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes.

Am Surg 2016 Nov;82(11):1109-1116

Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
November 2016

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

J Clin Oncol 2017 Mar 14;35(7):785-792. Epub 2016 Nov 14.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Suzanne L. Topalian, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Hewei Li, Ian M. Waxman, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; Dirk Schadendorf, University of Essen, Essen, Germany; James Larkin, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Georgina V. Long, Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia; and Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif-Paris Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1389DOI Listing
March 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

J Clin Oncol 2017 Jan 7;35(2):226-235. Epub 2016 Nov 7.

Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559888PMC
January 2017

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.

J Immunother Cancer 2016 20;4:85. Epub 2016 Dec 20.

Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612-9416 USA ; New York University Langone Medical Center, New York, NY USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0194-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170897PMC
December 2016

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

J Clin Oncol 2017 01 28;35(2):139-140. Epub 2016 Nov 28.

Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, PA; Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Adam P. Dicker, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Mithat Gönen, Memorial Sloan Kettering Cancer Center, New York, NY; Stephen M. Keefe, University of Pennsylvania, Philadelphia, PA; Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC; and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559890PMC
January 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

Comment on the American Society of Clinical Oncology Value Statement.

J Clin Oncol 2016 08 13;34(24):2937-8. Epub 2016 Jun 13.

University of Cambridge, Cambridge; Advent Life Sciences, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.3692DOI Listing
August 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Melanoma Res 2016 Feb;26(1):83-7

Departments of aCutaneous Oncology bAnatomic Pathology, Moffitt Cancer Center Departments of cOncologic Sciences dSurgery, University of South Florida Morsani College of Medicine eDepartment of Pathology, Veterans Administration, Tampa, Florida fDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia gGeorgetown-Lombardi Comprehensive Cancer Center and Department of Medicine, Medstar-Georgetown University Hospital, Washington, DC, USA hUniversity of Groningen, Department of Surgical Oncology, University Medical Center Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000214DOI Listing
February 2016

From the Guest Editor: Adoptive Cell Therapy: Fulfilling Its Promise.

Authors:
Jeffrey S Weber

Cancer J 2015 Nov-Dec;21(6):448-9

From Donald A. Adam Comprehensive Melanoma Center, Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000163DOI Listing
September 2016

Toxicities of Immunotherapy for the Practitioner.

J Clin Oncol 2015 Jun 27;33(18):2092-9. Epub 2015 Apr 27.

Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; James C. Yang, National Cancer Institute, Bethesda, MD; Michael B. Atkins, Lombardi Cancer Center, Georgetown University, Washington, DC; and Mary L. Disis, The Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881375PMC
June 2015

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

J Clin Oncol 2015 Jun 9;33(17):1889-94. Epub 2015 Feb 9.

Dirk Schadendorf, University Hospital Essen, Essen, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Caroline Robert, Institute Gustave Roussy, Villejuif, France; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; Kim Margolin, University of Washington, Seattle, WA; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Debra Patt, The US Oncology Network, McKesson Specialty Health, Houston, TX; Tai-Tsang Chen, Bristol-Myers Squibb, Wallingford, CT; David M. Berman, Bristol-Myers Squibb, Lawrenceville, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.2736
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.2736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089162PMC
June 2015

Cancer immunotherapy meets biomaterials.

Nat Biotechnol 2015 Jan;33(1):44-5

Moffitt Cancer Center, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.3119DOI Listing
January 2015

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.

Ther Adv Med Oncol 2015 Jan;7(1):12-21

Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Mailstop SRB 2, Tampa, FL 33162, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834014551747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265090PMC
January 2015

Classification of current anticancer immunotherapies.

Oncotarget 2014 Dec;5(24):12472-508

Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.

View Article

Download full-text PDF

Source
https://lirias.kuleuven.be/bitstream/123456789/502976/1/2998
Web Search
http://oncotarget.com/abstract/2998
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350348PMC
http://dx.doi.org/10.18632/oncotarget.2998DOI Listing
December 2014

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Clin Cancer Res 2015 Feb 18;21(4):712-20. Epub 2014 Dec 18.

Department of Cutaneous Oncology and Comprehensive Melanoma Research Center, Moffitt Cancer Center, Tampa, Florida. Department of Oncologic Sciences, University of South Florida, Tampa, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620684PMC
February 2015

LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

J Neurooncol 2015 Mar 18;122(1):121-6. Epub 2014 Dec 18.

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., Tampa, FL, 33612, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-014-1685-xDOI Listing
March 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

J Clin Oncol 2015 Jan 15;33(3):278-84. Epub 2014 Dec 15.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; Laura A. Levit and Suanna Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, Children's Hospital of Philadelphia; Adam P. Dicker, Jefferson Medical College, Thomas Jefferson University; Stephen M. Keefe and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA; Howard A. Burris IIII, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; Mithat Gönen and Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; and Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/278.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2635
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516884PMC
January 2015

Current perspectives on immunotherapy.

Authors:
Jeffrey S Weber

Semin Oncol 2014 Oct 8;41 Suppl 5:S14-29. Epub 2014 Sep 8.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.09.003DOI Listing
October 2014

Immuno-oncology comes of age-introduction.

Authors:
Jeffrey S Weber

Semin Oncol 2014 Oct 6;41 Suppl 5:S1-2. Epub 2014 Sep 6.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2014.09.002DOI Listing
October 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis.

Cell Rep 2014 Aug 31;8(3):871-882. Epub 2014 Jul 31.

Department of Cancer Immunotherapeutics & Tumor Immunology (CITI), City of Hope National Medical Center, 1500 E. Duarte Rd, Duarte, CA 91010, USA.

View Article

Download full-text PDF

Source
http://www.cell.com/cms/attachment/2027778619/2046154942/mmc
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S221112471400551
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2014.06.052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174572PMC
August 2014

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

Cancer Treat Rev 2014 Oct 7;40(9):1056-64. Epub 2014 Jul 7.

Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.06.012DOI Listing
October 2014

At the bedside: adoptive cell therapy for melanoma-clinical development.

Authors:
Jeffrey S Weber

J Leukoc Biol 2014 Jun 14;95(6):875-82. Epub 2014 Apr 14.

Moffitt Cancer Center and the Donald A. Adam Comprehensive Melanoma Research Center, Tampa, Florida, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.0513293DOI Listing
June 2014

Up close and personal: the challenges of precision medicine in melanoma.

J Natl Cancer Inst 2014 Feb;106(2):djt443

Affiliations of authors: Department of Cutaneous Oncology (KSMS, JSW), Department of Molecular Oncology (KSMS), Melanoma Research Center of Excellence (KSMS, JSW), Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt443DOI Listing
February 2014

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

J Clin Oncol 2013 Dec 21;31(34):4311-8. Epub 2013 Oct 21.

Jeffrey S. Weber, Ragini Reiney Kudchadkar, Bin Yu, Donna Gallenstein, Xiuhua Zhao, Alberto J. Martinez, Wenshi Wang, Geoffrey Gibney, Jodi Kroeger, Cabell Eysmans, Amod A. Sarnaik, and Y. Ann Chen, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and Christine E. Horak and H. David Inzunza, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.51.4802
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.51.4802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837092PMC
December 2013

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

J Clin Oncol 2013 Sep 17;31(26):3182-90. Epub 2013 Jun 17.

F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.7836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082PMC
September 2013

Ipilimumab and its toxicities: a multidisciplinary approach.

Oncologist 2013 Jun 17;18(6):733-43. Epub 2013 Jun 17.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063401PMC
June 2013

Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.

Clin Cancer Res 2013 Jul 5;19(14):3977-86. Epub 2013 Jun 5.

Bristol-Myers Squibb, Princeton, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3243DOI Listing
July 2013

Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations.

J Natl Cancer Inst 2013 May 27;105(9):591-2. Epub 2013 Mar 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt075DOI Listing
May 2013

Expanding targeted therapy to NRAS-mutated melanoma.

Lancet Oncol 2013 Mar 13;14(3):186-8. Epub 2013 Feb 13.

Department of Cutaneous Oncology and Melanoma Research Center of Excellence, Moffitt Cancer Center, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70054-8DOI Listing
March 2013

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Cancer 2013 May 7;119(9):1675-82. Epub 2013 Feb 7.

Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.27969
Publisher Site
http://dx.doi.org/10.1002/cncr.27969DOI Listing
May 2013

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

Sci Rep 2012 24;2:765. Epub 2012 Oct 24.

Cutaneous Oncology, Moffitt Cancer Center , Tampa, FL, USA ; the Departments of Pathology and Cell Biology, University of South Florida , Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep00765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479449PMC
March 2013

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

J Transl Med 2012 Jul 12;10:146. Epub 2012 Jul 12.

Department of Cutaneous Oncology and the Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-10-146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527361PMC
July 2012

T-cell therapy at the threshold.

Nat Biotechnol 2012 Jul 10;30(7):611-4. Epub 2012 Jul 10.

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nbt.2305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332500PMC
July 2012

Management of immune-related adverse events and kinetics of response with ipilimumab.

J Clin Oncol 2012 Jul 21;30(21):2691-7. Epub 2012 May 21.

H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.41.6750DOI Listing
July 2012

Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.

Authors:
Jeffrey S Weber

Am Soc Clin Oncol Educ Book 2012 :174-7

From the Moffitt Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.79DOI Listing
April 2016